ATE283047T1 - Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose - Google Patents

Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose

Info

Publication number
ATE283047T1
ATE283047T1 AT98936715T AT98936715T ATE283047T1 AT E283047 T1 ATE283047 T1 AT E283047T1 AT 98936715 T AT98936715 T AT 98936715T AT 98936715 T AT98936715 T AT 98936715T AT E283047 T1 ATE283047 T1 AT E283047T1
Authority
AT
Austria
Prior art keywords
ibudilast
multiple sclerosis
treatment
production
medicinal product
Prior art date
Application number
AT98936715T
Other languages
English (en)
Inventor
Saburo Sakoda
Original Assignee
Kyorin Seiyaku Kk
Saburo Sakoda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk, Saburo Sakoda filed Critical Kyorin Seiyaku Kk
Application granted granted Critical
Publication of ATE283047T1 publication Critical patent/ATE283047T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Forklifts And Lifting Vehicles (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicinal Preparation (AREA)
AT98936715T 1998-08-10 1998-08-10 Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose ATE283047T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1998/003548 WO2000009127A1 (en) 1998-08-10 1998-08-10 Remedies for multiple sclerosis

Publications (1)

Publication Number Publication Date
ATE283047T1 true ATE283047T1 (de) 2004-12-15

Family

ID=14208769

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98936715T ATE283047T1 (de) 1998-08-10 1998-08-10 Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose

Country Status (11)

Country Link
US (1) US6395747B1 (de)
EP (1) EP1106178B1 (de)
JP (1) JP4828003B2 (de)
AT (1) ATE283047T1 (de)
AU (1) AU8562198A (de)
CA (1) CA2339934C (de)
DE (1) DE69827853T2 (de)
DK (1) DK1106178T3 (de)
ES (1) ES2231998T3 (de)
PT (1) PT1106178E (de)
WO (1) WO2000009127A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4589122B2 (ja) * 2002-12-03 2010-12-01 杏林製薬株式会社 ホスホジエステラーゼ１０ａ阻害剤
DE602004031356D1 (de) * 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
US20060093578A1 (en) * 2004-11-04 2006-05-04 Kyorin Pharmaceutical Co., Ltd. Method and composition for treating multiple sclerosis
MX2007006777A (es) * 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
KR100780479B1 (ko) 2006-05-08 2007-11-28 윈셋파마 주식회사 이부딜라스트 함유 경구용 제제 및 이의 제조방법
WO2007142924A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
EP2131841B1 (de) * 2007-01-30 2012-08-01 Avigen, Inc. Verfahren zur behandlung von akuten schmerzen
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
PT2187882E (pt) * 2007-07-11 2013-04-17 Medicinova Inc Tratamento de uma doença neurodegenerativa progressiva com ibudilast
WO2018119262A1 (en) 2016-12-22 2018-06-28 Medicinova, Inc. Methods of treating glioblastoma multiforme using ibudilast
ES2959799T3 (es) * 2018-02-12 2024-02-28 Medicinova Inc Métodos para suprimir células supresoras de origen mieloide en pacientes
WO2019157423A1 (en) 2018-02-12 2019-08-15 Medicinova, Inc. Methods and dosing regimens using ibudilast and a second agent for cancer therapy
CA3135420A1 (en) * 2018-04-05 2019-10-10 Universiteit Hasselt Selective pde4d inhibitors against demyelinating diseases
CA3115269A1 (en) 2018-10-09 2020-04-16 Medicinova, Inc. Combination of ibudilast and interferon-beta and methods of using same
CN112804999B (zh) 2018-10-19 2024-03-15 美迪诺亚公司 通过异丁司特治疗眼科疾病/病症或损伤的方法
US12377074B2 (en) * 2019-06-11 2025-08-05 Yale University Treatment for Wolfram syndrome
US11865214B2 (en) 2019-09-23 2024-01-09 Medicinova, Inc. Ibudilast oral formulations and methods of using same
EP4132521A1 (de) 2020-04-06 2023-02-15 MediciNova, Inc. Verfahren zur reduzierung des plasmaspiegels des makrophagen-migrationshemmenden faktors bei patienten mit ibudilast
CN116887829A (zh) 2021-01-29 2023-10-13 美迪诺亚公司 治疗化学气体暴露的方法
US12005049B2 (en) 2021-07-26 2024-06-11 Medicinova, Inc. Methods of preventing cancer metastasis
WO2023049075A1 (en) 2021-09-21 2023-03-30 Medicinova, Inc. Ibudilast in combination therapy for use in the treatment of glioblastoma
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
JP2025504984A (ja) 2022-02-01 2025-02-19 メディシノバ・インコーポレイテッド Ｃｏｖｉｄ後症状の治療における使用のためのイブジラスト
CA3261163A1 (en) 2022-07-13 2024-01-18 Medicinova, Inc. INJECTABLE FORMULATIONS OF IBUDILAST
WO2026060180A1 (en) 2024-09-11 2026-03-19 Medicinova, Inc. Modified release formulations of ibudilast

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US5817670A (en) * 1994-08-29 1998-10-06 Yamanouchi Pharmaceutical Co., Ltd. Naphthyridine derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
US6395747B1 (en) 2002-05-28
WO2000009127A1 (en) 2000-02-24
AU8562198A (en) 2000-03-06
CA2339934C (en) 2008-06-03
JP4828003B2 (ja) 2011-11-30
ES2231998T3 (es) 2005-05-16
EP1106178B1 (de) 2004-11-24
EP1106178A4 (de) 2001-11-21
CA2339934A1 (en) 2000-02-24
PT1106178E (pt) 2005-02-28
DE69827853T2 (de) 2005-12-08
DK1106178T3 (da) 2005-02-28
DE69827853D1 (de) 2004-12-30
EP1106178A1 (de) 2001-06-13

Similar Documents

Publication Publication Date Title
DE69827853D1 (de) Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE69201948D1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE332702T1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
NO870241L (no) Hypoglykemiske tiazolidindioner.
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE3879873D1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE59302501D1 (de) Substituierte Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten
ATE353645T1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
DE3873578D1 (de) Verwendung von tetrahydrobenz(c,d)indol-6-carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
ATE335487T1 (de) Verwendung von pyridazino 4,5-(b)ö-indole-1- acetamide derivaten zur herstellung eines arzneimittels zur behandlung von durch periphere benzodiazepinrezeptoren-störungen verursachte krankheiten
ATE74006T1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
ATE184788T1 (de) Idebenone-haltige zusammensetzungen zur behandlung von m. alzheimer
ATE85334T1 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
ATE157871T1 (de) Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
ATE135573T1 (de) Verwendung von indazol-methoxyalkansäure zur herstellung eines arzneimittels zur behandlung von autoimmunkrankheiten
TNSN97143A1 (fr) Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant
KR880009957A (ko) 알킬-치환된 n-벤조피라닐락탐, 이의 제조방법, 이의 용도 및 이들 화합물을 기본으로 하는 약제학적 제제
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE169635T1 (de) Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen
ATE110568T1 (de) Pharmazeutisches präparat zur behandlung des katarakts.
KR950032191A (ko) 사이클로헥산 유도체, 이의 제조방법 및 질병을 치료하기 위한 화합물의 용도

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1106178

Country of ref document: EP